{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:57:44Z","timestamp":1789012664369,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"national institutes of health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.bbmt.2020.03.019","type":"journal-article","created":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T02:40:06Z","timestamp":1587264006000},"page":"1482-1491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Impact of Preemptive Therapy for Cytomegalovirus on Toxicities after Allogeneic Hematopoietic Cell Transplantation in Clinical Practice: A Retrospective Single-Center Cohort Study"],"prefix":"10.1016","volume":"26","author":[{"given":"Phaedon","family":"Zavras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8659-8108","authenticated-orcid":false,"given":"Anat","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitasha","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6528-4145","authenticated-orcid":false,"given":"Yuexin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Raval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann A.","family":"Jakubowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genovefa A.","family":"Papanicolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.bbmt.2020.03.019_bib0001","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1517\/14712598.2012.693471","article-title":"Therapeutic strategies for the prevention and treatment of cytomegalovirus infection","volume":"12","author":"Sellar","year":"2012","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"10.1016\/j.bbmt.2020.03.019_bib0002","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.bbmt.2020.03.019_bib0003","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.bbmt.2016.05.003","article-title":"Cytomegalovirus infection after CD34(+)-selected hematopoietic cell transplantation","volume":"22","author":"Huang","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"10.1016\/j.bbmt.2020.03.019_bib0004","doi-asserted-by":"crossref","first-page":"5689","DOI":"10.1182\/blood-2011-06-361618","article-title":"Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients","volume":"118","author":"Milano","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.03.019_bib0005","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/asheducation-2011.1.305","article-title":"Complications, diagnosis, management, and prevention of CMV infections: current and future","volume":"2011","author":"Boeckh","year":"2011","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"7","key":"10.1016\/j.bbmt.2020.03.019_bib0006","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood.V95.7.2240","article-title":"Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation","volume":"95","author":"Broers","year":"2000","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.bbmt.2020.03.019_bib0007","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.bbmt.2020.03.019_bib0008","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1182\/blood-2008-10-143560","article-title":"How we treat cytomegalovirus in hematopoietic cell transplant recipients","volume":"113","author":"Boeckh","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.03.019_bib0009","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/874601","article-title":"Improving safety of preemptive therapy with oral valganciclovir for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation","volume":"2012","author":"Barkam","year":"2012","journal-title":"Bone Marrow Res"},{"issue":"1","key":"10.1016\/j.bbmt.2020.03.019_bib0010","article-title":"CMV in hematopoietic stem cell transplantation","volume":"8","author":"de la Camara","year":"2016","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"4","key":"10.1016\/j.bbmt.2020.03.019_bib0011","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/bmt.2008.162","article-title":"Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT","volume":"42","author":"Ljungman","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bbmt.2020.03.019_bib0012","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.V99.4.1159","article-title":"Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation","volume":"99","author":"Reusser","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bbmt.2020.03.019_bib0013","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12185-008-0249-2","article-title":"Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients","volume":"89","author":"Takenaka","year":"2009","journal-title":"Int J Hematol"},{"issue":"6","key":"10.1016\/j.bbmt.2020.03.019_bib0014","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/tid.12456","article-title":"Occurrence of adverse events caused by valganciclovir as pre-emptive therapy for cytomegalovirus infection after allogeneic stem cell transplantation is reduced by low-dose administration","volume":"17","author":"Takahata","year":"2015","journal-title":"Transplant Infect Dis"},{"issue":"7","key":"10.1016\/j.bbmt.2020.03.019_bib0015","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3851\/IMP1858","article-title":"Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients","volume":"16","author":"Ruiz-Camps","year":"2011","journal-title":"Antiviral Ther"},{"issue":"3","key":"10.1016\/j.bbmt.2020.03.019_bib0016","doi-asserted-by":"crossref","first-page":"173","DOI":"10.7326\/0003-4819-118-3-199302010-00003","article-title":"Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant","volume":"118","author":"Goodrich","year":"1993","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.bbmt.2020.03.019_bib0017","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-118-3-199302010-00004","article-title":"Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of a placebo-controlled, double-blind trial","volume":"118","author":"Winston","year":"1993","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.bbmt.2020.03.019_bib0018","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1182\/blood.V90.6.2502","article-title":"Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome","volume":"90","author":"Salzberger","year":"1997","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bbmt.2020.03.019_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M13-2729","article-title":"Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial","volume":"162","author":"Boeckh","year":"2015","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.bbmt.2020.03.019_bib0020","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.bbmt.2020.03.019_bib0021","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1086\/367836","article-title":"Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation","volume":"36","author":"Winston","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.bbmt.2020.03.019_bib0022","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/1469-0691.12222","article-title":"Risk factors of ganciclovir-related neutropenia after allogeneic stem cell transplantation: a retrospective monocentre study on 547 patients","volume":"20","author":"Venton","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"10.1016\/j.bbmt.2020.03.019_bib0023","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1586\/eri.12.115","article-title":"Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients","volume":"10","author":"Bacigalupo","year":"2012","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"10","key":"10.1016\/j.bbmt.2020.03.019_bib0024","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1097\/TP.0000000000001418","article-title":"Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection","volume":"100","author":"Avery","year":"2016","journal-title":"Transplantation"},{"issue":"17","key":"10.1016\/j.bbmt.2020.03.019_bib0025","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2146\/ajhp090424","article-title":"Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection","volume":"67","author":"Jacobsen","year":"2010","journal-title":"Am J Health Syst Pharm"},{"issue":"7","key":"10.1016\/j.bbmt.2020.03.019_bib0026","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/bmt.2016.36","article-title":"A novel reduced intensity conditioning regimen for patients with high-risk hematological malignancies undergoing allogeneic stem cell transplantation","volume":"51","author":"Hobbs","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bbmt.2020.03.019_bib0027","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.bbmt.2019.10.003","article-title":"Ex vivo T cell-depleted hematopoietic stem cell transplantation for adult patients with acute myelogenous leukemia in first and second remission: long-term disease-free survival with a significantly reduced risk of graft-versus-host disease","volume":"26","author":"Montoro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.bbmt.2020.03.019_bib0028","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.bbmt.2017.06.008","article-title":"Co-infections by double-stranded DNA viruses after ex vivo T cell-depleted, CD34(+) selected hematopoietic cell transplantation","volume":"23","author":"Huang","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bbmt.2020.03.019_bib0029","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.bbmt.2015.08.025","article-title":"CD34-selected allogeneic hematopoietic stem cell transplantation for patients with relapsed, high-risk multiple myeloma","volume":"22","author":"Smith","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bbmt.2020.03.019_bib0030","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3109\/10428194.2014.930851","article-title":"Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant","volume":"56","author":"Ceberio","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.bbmt.2020.03.019_bib0031","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bbmt.2019.05.025","article-title":"Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide-based haploidentical versus matched sibling donor reduced-intensity conditioning transplant for Hodgkin lymphoma","volume":"25","author":"Ahmed","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bbmt.2020.03.019_bib0032","doi-asserted-by":"crossref","first-page":"e12897","DOI":"10.1111\/tid.12897","article-title":"Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"20","author":"Rosillo","year":"2018","journal-title":"Transplant Infect Dis"},{"issue":"4","key":"10.1016\/j.bbmt.2020.03.019_bib0033","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jinf.2014.06.004","article-title":"Impact of peri-transplant vancomycin and fluoroquinolone administration on rates of bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients: a 12-year single institution study","volume":"69","author":"Seo","year":"2014","journal-title":"J Infect"},{"issue":"4","key":"10.1016\/j.bbmt.2020.03.019_bib0034","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1128\/JCM.03435-14","article-title":"Monitoring of cytomegalovirus viral loads by two molecular assays in whole-blood and plasma samples from hematopoietic stem cell transplant recipients","volume":"53","author":"Babady","year":"2015","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.bbmt.2020.03.019_bib0035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.bbmt.2020.03.019_bib0036","first-page":"825","article-title":"1994 Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.bbmt.2020.03.019_bib0037","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1182\/blood.V86.7.2815.2815","article-title":"Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation","volume":"86","author":"Einsele","year":"1995","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bbmt.2020.03.019_bib0038","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/bmt.2015.44","article-title":"Racial differences in allogeneic hematopoietic cell transplantation outcomes among African Americans and whites","volume":"50","author":"Hamilton","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bbmt.2020.03.019_bib0039","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/bmt.2009.180","article-title":"Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience","volume":"45","author":"Pinana","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bbmt.2020.03.019_bib0040","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/tid.12398","article-title":"Risk factors and prognostic scale for cytomegalovirus (CMV) infection in CMV-seropositive patients after allogeneic hematopoietic cell transplantation","volume":"17","author":"Cohen","year":"2015","journal-title":"Transpl Infect Dis"},{"issue":"5","key":"10.1016\/j.bbmt.2020.03.019_bib0041","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/bmt.2016.343","article-title":"Long term renal survival in patients undergoing T-Cell depleted versus conventional hematopoietic stem cell transplants","volume":"52","author":"Glezerman","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.bbmt.2020.03.019_bib0042","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMoa1714656","article-title":"Maribavir for preemptive treatment of cytomegalovirus reactivation","volume":"381","author":"Maertens","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.bbmt.2020.03.019_bib0043","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1128\/AAC.31.3.452","article-title":"Toxicity of 3\u2032-azido-3\u2032-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro","volume":"31","author":"Sommadossi","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 3","key":"10.1016\/j.bbmt.2020.03.019_bib0044","doi-asserted-by":"crossref","first-page":"S507","DOI":"10.1093\/clinids\/10.Supplement_3.S507","article-title":"Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function","volume":"10","author":"Sommadossi","year":"1988","journal-title":"Rev Infect Dis"},{"issue":"3","key":"10.1016\/j.bbmt.2020.03.019_bib0045","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/clpt.1986.177","article-title":"Human pharmacokinetics of the antiviral drug DHPG","volume":"40","author":"Fletcher","year":"1986","journal-title":"Clin Pharmacol Ther"},{"issue":"25","key":"10.1016\/j.bbmt.2020.03.019_bib0046","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.bbmt.2020.03.019_bib0047","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/cid\/ciy706","article-title":"Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study","volume":"68","author":"Papanicolaou","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"suppl 2","key":"10.1016\/j.bbmt.2020.03.019_bib0048","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/S1386-6532(02)00092-6","article-title":"Cytomegalovirus mediated myelosuppression","volume":"25","author":"Randolph-Habecker","year":"2002","journal-title":"J Clin Virol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120301774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120301774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:12:34Z","timestamp":1761059554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879120301774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S1083879120301774"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.03.019","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Preemptive Therapy for Cytomegalovirus on Toxicities after Allogeneic Hematopoietic Cell Transplantation in Clinical Practice: A Retrospective Single-Center Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}